BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst (Nasdaq: BCRX) announced that its compensation committee granted a newly hired employee 18,300 restricted stock units (RSUs) as inducement equity under Nasdaq Listing Rule 5635(c)(4).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioCryst (Nasdaq: BCRX) announced that its compensation committee granted a newly hired employee 18,300 restricted stock units (RSUs) as inducement equity under Nasdaq Listing Rule 5635(c)(4).
The RSUs were granted effective January 2, 2026, vest in four equal annual installments beginning on the one-year anniversary of the grant date, and are subject to the recipient’s continued service and the terms of BioCryst’s Inducement Equity Incentive Plan and a restricted stock unit agreement.
Details
News Market Reaction – BCRX
On Jan 6, the day this news came out, BCRX closed 2.29% above the previous close.
Data tracked by StockTitan Argus for the Jan 6 session.
Key Figures
- RSU grant size
- 18,300 shares
- Inducement RSUs to one newly hired employee effective Jan 2, 2026
- Vesting schedule
- 4 annual installments
- RSUs vest in four equal annual installments from first anniversary
Historical Context
-
ORLADEYO oral pellets FDA approval for pediatric HAE prophylaxis.
-
Inducement stock options and RSUs for four new hires.
-
Early termination of HSR waiting period for Astria acquisition.
-
Astria Q3 2025 financials and details of BCRX acquisition terms.
-
New APeX-P pediatric ORLADEYO data and burden-of-illness findings.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
restricted stock units financial
nasdaq listing rule 5635(c)(4) regulatory
inducement equity incentive plan financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted one newly-hired employee restricted stock units (RSUs) covering an aggregate of 18,300 shares of BioCryst common stock. The RSUs were granted as of January 2, 2026, as inducements material to such employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. The RSUs are subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a restricted stock unit agreement covering the grant.
About BioCryst Pharmaceuticals
BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics for a range of rare diseases. For more information, please visit www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:
Investors:
investorrelations@biocryst.com
Media:
media@biocryst.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.